Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms
Fig 8
Identified Tier I and Tier II mutations in 44 genes from the total cohort of 2,053 patients detected by the 48-gene NGS panel for myeloid neoplasms.
Each column in the x = axis represents a patient. Only patients with at least 1 mutation (n = 1,142) are shown. The percent of patients with Tier I and Tier II mutations in the indicated gene is presented.